EW
Edwards Lifesciences Corporation
Healthcare · Medical Devices · United States · Stock
Score Breakdown
Scored for Safe Long-Term Investing profile
Sub-scores are 0–20 each; Model Score is weighted by your selected investment goal. How it works →
Why Ranked Here
- Strong revenue growth of +11.5% and solid FY2025 profitability margins contributed positively, but the 74.3% collapse in net income heavily penalized the growth factor score.
- Quarterly momentum was mixed: revenue accelerated steadily, but the pronounced dip in operating and net income mid-period limited the momentum score to near-midpoint.
- The absence of any dividend payment and the failure of the Aging Population theme assignment to generate a positive score contribution left two factors at zero, pulling the composite score down significantly.
Why Not Higher
- The steep decline in net income and diluted EPS — net income falling 74.3% and EPS dropping from $6.97 to $1.83 — created a major drag on the growth factor and overall composite score.
- Zero scores on both the dividend and theme factors, combined with volatile quarterly earnings, prevented the otherwise solid profitability metrics from lifting the total score above the medium-risk range.
Data Confidence
8 / 10
High — most data fields present
Why This Score
Grounded in figures from this company's SEC EDGAR filings — not a restatement of the score itself.
Revenue grew from FY2024's $5,439,500,000 to FY2025's $6,067,600,000, a gain of +11.5%. However, net income fell sharply from FY2024's $4,174,600,000 to FY2025's $1,073,500,000 (-74.3%), and diluted EPS dropped from FY2024's $6.97 to FY2025's $1.83 (-73.7%).
The model rewarded the solid top-line expansion but heavily penalized the steep decline in bottom-line profitability, resulting in a below-midpoint score that reflects the tension between revenue growth and earnings contraction.
In FY2025, Edwards Lifesciences posted an operating margin of 20.8%, a net margin of 17.7%, and a return on assets of 7.8%.
These metrics indicate that the company converts a meaningful share of revenue into operating and net income while generating solid returns on its asset base, which the model rewarded with a high sub-score.
Filing evidence currently available does not support a more specific explanation for this factor.
Quarterly revenue showed a steady upward trend from 2025Q2's $1,532,200,000 through 2026Q1's $1,648,600,000. Operating income, however, was volatile, dipping to $151,100,000 in 2025Q4 before rebounding to $477,600,000 in 2026Q1. Net income followed a similarly uneven path, falling to $91,200,000 in 2025Q4 and recovering to $380,700,000 in 2026Q1.
The model recognized the consistent revenue acceleration but discounted the score due to the pronounced mid-period weakness in earnings and operating income, producing a near-midpoint result that reflects mixed momentum signals.
Edwards Lifesciences does not currently pay a dividend; this is a genuine characteristic of the company, not a data limitation.
Because the model rewards dividend income and yield, a confirmed non-payer receives the minimum score on this factor.
Edwards Lifesciences is assigned to the Aging Population macro theme.
Although the company is linked to a tracked macro theme that is broadly relevant to its cardiac and critical-care device business, this assignment did not translate into a positive score under the model's current methodology.
Research Summary
AI-generated analysis reflects data and conditions as of the report date shown above. Verify any specific figures through primary sources before acting on this analysis.
Edwards Lifesciences delivered solid top-line growth of +11.5% year-over-year, with revenue rising from $5.44 billion in FY2024 to $6.07 billion in FY2025, while maintaining a respectable operating margin of 20.8% and net margin of 17.7% in FY2025. However, net income collapsed by 74.3% and diluted EPS fell from $6.97 to $1.83, creating a sharp tension between revenue expansion and earnings contraction. Quarterly momentum shows consistent revenue acceleration but volatile operating and net income, with a notable trough in 2025Q4 followed by a partial recovery in 2026Q1. The company pays no dividend and its macro theme assignment did not contribute positively to the model score, resulting in a composite rating of Medium risk with a label of Research Further.
Plain English
Edwards Lifesciences is growing its sales nicely, but its profits dropped dramatically last year, and it doesn't pay dividends, so while the business looks solid on the surface, there are enough question marks that it's worth digging deeper before making any decisions.
Bull Case vs. Bear Case
Bull Case
- Revenue grew a healthy +11.5% year-over-year, from $5.44 billion to $6.07 billion, demonstrating consistent top-line momentum across the business.
- The company maintains strong profitability metrics in FY2025, including a 20.8% operating margin, 17.7% net margin, and 7.8% return on assets, indicating efficient conversion of revenue into income.
- Quarterly revenue has trended steadily upward from $1.53 billion in 2025Q2 to $1.65 billion in 2026Q1, suggesting durable demand for the company's products.
Bear Case
- Net income plunged 74.3% from $4.17 billion in FY2024 to $1.07 billion in FY2025, and diluted EPS dropped from $6.97 to $1.83, signaling a severe deterioration in bottom-line profitability.
- Operating income was highly volatile on a quarterly basis, falling as low as $151.1 million in 2025Q4 before rebounding to $477.6 million in 2026Q1, raising concerns about earnings consistency.
- The company pays no dividend, meaning investors receive no income return while bearing the uncertainty of the earnings volatility described above.
What Could Change the Picture
Bullish Triggers
- A sustained recovery in quarterly net income and operating income above the 2025Q4 trough levels, building on the 2026Q1 rebound to $380.7 million and $477.6 million respectively, could signal that the earnings contraction was temporary.
- If the Aging Population macro theme begins to translate into a measurable model score contribution, it could reflect stronger recognition of the structural demand tailwind for cardiac and critical-care devices.
Bearish Triggers
- If quarterly operating income fails to sustain its 2026Q1 recovery and revisits the weakness seen in 2025Q4, it would reinforce concerns that the earnings decline is structural rather than transitory.
- A further widening of the gap between revenue growth and net income growth would suggest that cost pressures or one-time charges are becoming a persistent drag on profitability.
Red Flags
- ONE_TIME_REVIEW: 2024 OCF/NI ratio = 0.13 (OCF=542,300,000, NI=4,174,600,000) — possible large one-time item
Risk Profile
Medium RiskQuarterly earnings showed significant instability, with operating income dropping to $151.1 million in 2025Q4 before recovering to $477.6 million in 2026Q1, and net income following a similarly uneven path, indicating that near-term profitability is not yet on a stable trajectory. The company holds $13.70 billion in total assets, providing a substantial balance sheet base, though the financial health factor's specific details are not fully elaborated in available filing evidence.
This report is for educational and research purposes only. It does not constitute financial, investment, legal, or tax advice — always conduct your own due diligence before making investment decisions.